Skip to main content

Table 1 List of differentially expressed genes following MST-312 treatment in brain tumour cells

From: Targeting DNA-PKcs and telomerase in brain tumour cells

Gene symbol

KNS60*

ONS76*

Cell cycle proteins

  

CCNB1

-1.59

1.49

BIRC5

-1.32

2.50

BIRC6

-1.51

-1.52

ANAPC4

-1.40

1.11

DNA damage response proteins

  

ATM

-1.58

-1.16

RAD 50

-1.85

-1.68

BRCA1

1.02

1.48

PARP1

1.11

1.31

ERCC5

1.27

-1.04

BLM

-1.59

1.20

APTX

-1.26

-1.57

DAPK3

1.10

1.48

Telomere and Telomerase

  

TIN2

-1.57

-1.16

TERF1

1.21

-1.02

TERF2

1.76

-1.48

c-MYC

-2.75

-2.25

DKC1

-1.19

-1.58

MRE11A

-1.34

1.00

RAD50

-1.85

-1.68

RFC1

-1.28

-1.31

TNKS1BP1

1.33

-1.82

PRPF31

-1.39

1.06

PRKCA

1.40

-2.23

NF-kB family

  

NFKBIZ

-1.91

-2.85

NFKBIE

1.28

1.83

NFKB2

1.26

-1.33

NFKBIB

1.29

-1.01

IRAK2

2.25

-2.00

Tumour necrosis factor

  

TNFSF10

-1.17

-3.80

TNFSF12

1.30

-1.01

MAD1L1

1.32

-1.02

Transforming growth factor

  

TGFB2

-1.90

-1.61

TGFBRAP1

1.39

1.18

TGFB1

1.62

-1.22

TGFBR3

-2.05

-2.05

SMAD1

1.11

-1.10

SMAD2

-1.06

-1.10

SMAD3

1.28

-1.51

SMAD4

1.32

-1.38

SMAD5

1.04

-1.34

SMAD6

-1.00

1.49

SMAD7

-1.96

-1.69

Mitochondrial function regulators

  

PGC-1α

1.22

-1.33

PGC-1β

1.04

-1.25

  1. Functional groupings/clusters of differentially expressed following 48 hours treatment with telomerase inhibitor (1.0 μM MST-312) in glioblastoma cells KNS60 and medulloblastoma cells ONS76. List of selected genes that showed significant fold changes (P <0.05) in at least in one of the tumour cells following MST-312 treatment (*) as compared to their respective controls. Data indicates statistically significant (bold) compared with respective untreated controls.